Skip to main content
. Author manuscript; available in PMC: 2020 Jun 25.
Published in final edited form as: Int J Toxicol. 2010 May-Jun;29(3):291–296. doi: 10.1177/1091581810362804

Table 3.

Tumors and Proliferative Lesions in Female Tg.AC Mice Exposed to Arsenic In Utero and Postnatal TPAa

Urinary Bladder, n (%)
 Uterus, n (%)
Treatment Group n Adrenal Adenoma, n (%) Hyperplasia Papilloma Hyperplasia Adenoma Leiomyoma
Control 25 0 (0) 0 (0) 0 (0) 1 (4.0) 0 (0) 0 (0)
TPA alone 24 0 (0) 0 (0) 0 (0) 1 (4.0) 0 (0) 0 (0)
As (42.5) 23 4 (17)b 6 (26)b 1 (4.3)c 9 (39)b 1 (4.3) 1 (4.3)
As (85) 24 4 (17)d 3 (13) 0 (0) 8 (33)b 0 (0) 1 (4.2)
As (42.5) + TPA 23 6 (26)b 7 (30)b 1 (4.3)c 6 (26)b 0 (0) 0 (0)
As (85) + TPA 25 5 (20)b 8 (32)b 0 (0) 10 (40)b 0 (0) 0 (0)

As, arsenic; TPA, 12-O-tetradecanoyl phorbol-13-acetate.

a

See Table 2 for details.

b

Significant difference (P < .05) from control.

c

Both urinary bladder papillomas occurred in mice that also had separate areas of hyperplasia.

d

Approached statistical significance from control (P = .0502).